These data provide evidence that MLN4924 selectively inhibits MMP9 activity in ESCC cells and confirm the presence of alterations in the composition of MMP9-associated transcriptional regulators under the treatment with MLN4924. This evidence concerns the gene MMP9 and esophageal squamous cell carcinoma.